FTXHvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with FTXH, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
FTXH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/28/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | FTXH ETF 2 | +3.28%– | +9.09%– | +31.84%– | +47.80%– | +87.39%– | +77.36%– |
| Flows | FTXH ETF 2 | +$41M– | +$176M– | +$1.02B– | +$1.02B– | +$1.02B– | +$1.02B– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | FTXH ETF 2 | +18.78%– | +17.62%– | +17.11%– | +16.43%– |
| Max drawdown | FTXH ETF 2 | -5.45%– | -7.50%– | -19.32%– | -19.32%– |
| Max drawdown duration | FTXH ETF 2 | 57d– | 99d– | 393d– | 393d– |
Trading data
FTXH | ETF 2 | |
Last sale 10/29/2026 at 1:30 PM | $43.77 | – |
| Previous close 10/28/2026 | $43.25 | – |
| Consolidated volume 10/28/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
FTXH | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/29/2026 at 1:30 PM
Live
Closed
FTXH | ETF 2 | |
|---|---|---|
| Last price | $43.77 | – |
| 1D performance | +1.22% | – |
| AuM | $1.16 B | – |
| E/R | 0.6% | – |
Characteristics
FTXH | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | First Trust | – |
| Benchmark | NASDAQ US Smart Pharmaceuticals Index | – |
| N° of holdings | 49 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | September 20, 2016 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
FTXH
USA
95.82%
Other
4.18%
ETF 2
Sectors
FTXH
Healthcare
99.79%
Other
0.21%
ETF 2
Diversification
FTXH
Total weight of top 15 holdings out of 15
67.15%
ETF 2
–
Top 15 holdings
Data as of August 31, 2026
FTXH
Merck & Co., Inc.
7.62%
AbbVie, Inc.
7.05%
Eli Lilly & Co.
6.92%
Johnson & Johnson
6.87%
Bristol Myers Squibb Co.
6.75%
Amgen, Inc.
3.56%
Biogen, Inc.
3.54%
Viatris, Inc.
3.51%
Vertex Pharmaceuticals, Inc.
3.48%
Regeneron Pharmaceuticals, Inc.
3.33%
Cardinal Health, Inc.
3.29%
Pfizer Inc.
3.25%
Gilead Sciences, Inc.
3.16%
Incyte Corp.
2.43%
United Therapeutics Corp.
2.39%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
